ORAGENICS INC (OGEN) Stock Overview
USA - NYSEARCA:OGEN - US6840236094 - Common Stock
OGEN Key Statistics, Chart & Performance
The current stock price of OGEN is 1.23 USD. In the past month the price decreased by -8.89%. In the past year, price decreased by -86.19%.
OGEN Latest News, Press Relases and Analysis
OGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Related stock screener links
About OGEN
Company Profile
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. The company is headquartered in Sarasota, Florida and currently employs 3 full-time employees. The company went IPO on 2003-07-09. The company is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The company is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
Company Info
ORAGENICS INC
1990 Main Street, Suite 750
Sarasota FLORIDA 33634 US
CEO: Alan Joslyn
Employees: 4
Phone: 18132867900
ORAGENICS INC / OGEN FAQ
What does ORAGENICS INC do?
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. The company is headquartered in Sarasota, Florida and currently employs 3 full-time employees. The company went IPO on 2003-07-09. The company is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The company is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
What is the current price of OGEN stock?
The current stock price of OGEN is 1.23 USD. The price decreased by -4.65% in the last trading session.
Does OGEN stock pay dividends?
OGEN does not pay a dividend.
How is the ChartMill rating for ORAGENICS INC?
OGEN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the analyst forecast for OGEN stock?
7 analysts have analysed OGEN and the average price target is 2.04 USD. This implies a price increase of 65.85% is expected in the next year compared to the current price of 1.23.
What is the employee count for OGEN stock?
ORAGENICS INC (OGEN) currently has 4 employees.
Can you provide the market cap for ORAGENICS INC?
ORAGENICS INC (OGEN) has a market capitalization of 5.08M USD. This makes OGEN a Nano Cap stock.
OGEN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to OGEN. When comparing the yearly performance of all stocks, OGEN is a bad performer in the overall market: 95.93% of all stocks are doing better.
OGEN Financial Highlights
Over the last trailing twelve months OGEN reported a non-GAAP Earnings per Share(EPS) of -56.05. The EPS increased by 78.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -717.68% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OGEN Forecast & Estimates
7 analysts have analysed OGEN and the average price target is 2.04 USD. This implies a price increase of 65.85% is expected in the next year compared to the current price of 1.23.